Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 9/20 | 0.42 |
| ▸ | ESR1 | P03372 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | YES1 | P07947 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2063039 | 0.80 | TSHR (0.56) | ESR2ESR1CYP3A4CYP19A1NPC1 | |
| SCHEMBL2063957 | 0.80 | TSHR (0.56) | ESR2ESR1CYP3A4CYP19A1NPC1 | |
| SCHEMBL5162162 | 0.75 | TSHR (0.64) | CYP3A4CYP19A1ADORA3MEN1KMT2A | |
| SCHEMBL9417485 | 0.73 | TSHR (0.61) | CYP19A1ADORA3MEN1KMT2AHSD17B10 | |
| SCHEMBL29555382 | 0.73 | TSHR (0.61) | CYP19A1ADORA3MEN1KMT2AHSD17B10 | |
| Phenol SCHEMBL2208770 | 0.73 | TSHR (0.67) | ESR2CYP3A4CYP19A1NPC1MAPT | |
| SCHEMBL29000962 | 0.71 | ESR2 (0.50) | ESR2ESR1CYP3A4CYP19A1NPC1 | |
| SCHEMBL7606736 | 0.69 | TSHR (0.59) | ESR2ESR1CYP3A4NPC1MAPT | |
| SCHEMBL12987805 | 0.68 | ESR2 (0.52) | ESR2ESR1CYP3A4ALOX15TTR | |
| SCHEMBL14185372 | 0.67 | CHRM2 (0.50) | ESR2CYP3A4CYP19A1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281092-B2 | Compound or salt thereof, composition, chemiluminescence method, method for measuring chemiluminescence signal, reagent, reagent kit, and method for assaying analyte | SYSMEX CORPORATION (JP) | 2025-04-22 | — | — | US | disclosed |
| US-20230242499-A1 | COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTE | SYSMEX CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
| EP-4219651-A1 | COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTE | SYSMEX CORPORATION (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-20180299456-A1 | In Situ Chemiluminescent Substrates and Assays | Life Technologies Corporation | 2018-10-18 | — | — | US | disclosed |
| US-10031142-B2 | In situ chemiluminescent substrates and assays | Life Technologies Corporation (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2590958-B1 | IN SITU CHEMILUMINESCENT SUBSTRATES AND ASSAYS | LIFE TECHNOLOGIES CORP (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20140186831-A1 | Solid Phases Optimized for Chemiluminescent Detection | Life Technologies Corporation (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130196325-A1 | In Situ Chemiluminescent Substrates and Assays | Life Technologies Corporation (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2590958-A1 | IN SITU CHEMILUMINESCENT SUBSTRATES AND ASSAYS | Life Technologies Corporation (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012006351-A1 | IN SITU CHEMILUMINESCENT SUBSTRATES AND ASSAYS | Life Technologies Corporation (US) | 2012-01-12 | — | — | WO | disclosed |
| EP-2163897-A1 | Solid phases optimized for chemiluminescent detection | Applied Biosystems, LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1470422-B8 | SOLID PHASES OPTIMIZED FOR CHEMILUMINESCENT DETECTION | APPLIED BIOSYSTEMS LLC (US) | 2009-10-07 | — | — | EP | disclosed |
| EP-2101174-A1 | Solid phases optimized for chemiluminescent detection | Applied Biosystems, LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-1470422-B1 | SOLID PHASES OPTIMIZED FOR CHEMILUMINESCENT DETECTION | APPLERA CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080227124-A1 | Multilayer support of polylactone or polyamide and cationic polymer; bioassay; kits | APPLIED BIOSYSTEMS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-7368296-B2 | Multilayer support of polylactone or polyamide and cationic polymer | APPLIED BIOSYSTEMS (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1470422-A4 | SOLID PHASES OPTIMIZED FOR CHEMILUMINESCENT DETECTION | APPLERA CORP (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1470422-A2 | SOLID PHASES OPTIMIZED FOR CHEMILUMINESCENT DETECTION | Applera Corporation (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003062790-A2 | SOLID PHASES OPTIMIZED FOR CHEMILUMINESCENT DETECTION | APPLERA CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030134286-A1 | Multilayer support of polylactone or polyamide and cationic polymer | APPLIED BIOSYSTEMS, INC. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180299456-A1 | In Situ Chemiluminescent Substrates and Assays | DNASE1L3, DCLRE1B, RNASE1 | ESR2 2912/4885ESR1 1803/4885CYP3A4 1535/4885 |
| US-10031142-B2 | In situ chemiluminescent substrates and assays | DNASE1L3, DCLRE1B, RNASE1 | ESR2 2912/4885ESR1 1803/4885CYP3A4 1535/4885 |
| US-12281092-B2 | Compound or salt thereof, composition, chemiluminescence method, method for measuring chemiluminescence signal, reagent, reagent kit, and method for assaying analyte | JAK2, MPO, PEAK1 | ESR2 4390/4885ESR1 3411/4885CYP3A4 2373/4885 |
| US-20230242499-A1 | COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTE | JAK2, MPO, PEAK1 | ESR2 4390/4885ESR1 3411/4885CYP3A4 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.